Aurobindo Pharma to replace Actavis' drugs with its own to lower cost: Report

21 Nov 2014 Evaluate

Aurobindo Pharma has decided to replace about 600 products of Actavis with its own low-cost high-margin products to bring down its overall costs. Early this year, the company had acquired the commercial operations of Actavis Plc in seven Western European countries for €30 million. To bring down the overall cost Aurobindo is switching the Actavis product with its own. Out of 450 molecules, 200 are likely to be replaced while in terms of products forms, 600 out of 1,200 could be replaced over the next 24 months, depending on R&D and manufacturing capacity creation in Aurobindo. This replacement would reduce the cost and improve the margins

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×